FDA Overhauls Its Purple Book
Searchable Biologics Database Is Welcomed By Biosimilars Industry
Executive Summary
The US FDA has overhauled its ‘Purple Book’ to make it a searchable database of biologics information. The agency is also seeking input on next steps.
You may also be interested in...
From Interchangeability To Invisibility: FDA Wipes Designation From Biosimilar Labels
Amid continuing stakeholder confusion over the meaning and significance of the US FDA’s interchangeability designation for biosimilars, the agency has now recommended omitting altogether details of interchangeability from biosimilar labels.
From Interchangeability To Invisibility: FDA Wipes Designation From Biosimilar Labels
Amid continuing stakeholder confusion over the meaning and significance of the US FDA’s interchangeability designation for biosimilars, the agency has now recommended omitting altogether details of interchangeability from biosimilar labels.
Purple Book Changes May Not Go Far Enough
Despite new requirements to include details of biologic exclusivity and intellectual property in the FDA’s Purple Book that come into effect on 25 June, experts believe information gaps for biosimilars developers may still exist.